Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Expression of D-Amino Acid Oxidase (DAO/DAAO) and D-Amino Acid Oxidase Activator (DAOA/G72) during Development and Aging in the Human Post-mortem Brain.

Jagannath V, Marinova Z, Monoranu CM, Walitza S, Grünblatt E.

Front Neuroanat. 2017 Apr 6;11:31. doi: 10.3389/fnana.2017.00031. eCollection 2017.

2.

Magnetoencephalography as a Tool in Psychiatric Research: Current Status and Perspective.

Uhlhaas PJ, Liddle P, Linden DEJ, Nobre AC, Singh KD, Gross J.

Biol Psychiatry Cogn Neurosci Neuroimaging. 2017 Apr;2(3):235-244. doi: 10.1016/j.bpsc.2017.01.005. Review.

3.
4.

Efficacy of Memantine in Schizophrenic Patients: A Systematic Review.

Di Iorio G, Baroni G, Lorusso M, Montemitro C, Spano MC, di Giannantonio M.

J Amino Acids. 2017;2017:7021071. doi: 10.1155/2017/7021071. Epub 2017 Jan 24. Review.

5.

Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function.

Braun U, Schäfer A, Bassett DS, Rausch F, Schweiger JI, Bilek E, Erk S, Romanczuk-Seiferth N, Grimm O, Geiger LS, Haddad L, Otto K, Mohnke S, Heinz A, Zink M, Walter H, Schwarz E, Meyer-Lindenberg A, Tost H.

Proc Natl Acad Sci U S A. 2016 Nov 1;113(44):12568-12573. Epub 2016 Oct 17.

6.

Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256.

Grannan MD, Mielnik CA, Moran SP, Gould RW, Ball J, Lu Z, Bubser M, Ramsey AJ, Abe M, Cho HP, Nance KD, Blobaum AL, Niswender CM, Conn PJ, Lindsley CW, Jones CK.

ACS Chem Neurosci. 2016 Dec 21;7(12):1706-1716. doi: 10.1021/acschemneuro.6b00230. Epub 2016 Oct 5.

PMID:
27617634
7.

Multifactorial Modeling of Impairment of Evoked Gamma Range Oscillations in Schizophrenia.

Metzner C, Schweikard A, Zurowski B.

Front Comput Neurosci. 2016 Aug 26;10:89. doi: 10.3389/fncom.2016.00089. eCollection 2016.

8.

Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials.

Marini S, De Berardis D, Vellante F, Santacroce R, Orsolini L, Valchera A, Girinelli G, Carano A, Fornaro M, Gambi F, Martinotti G, Di Giannantonio M.

Mediators Inflamm. 2016;2016:3476240. doi: 10.1155/2016/3476240. Epub 2016 Jul 25. Review.

9.

Mitochondrial Oxidative Phosphorylation System (OXPHOS) Deficits in Schizophrenia: Possible Interactions with Cellular Processes.

Bergman O, Ben-Shachar D.

Can J Psychiatry. 2016 Aug;61(8):457-69. doi: 10.1177/0706743716648290.

10.

Fractal Dimension Analysis of Subcortical Gray Matter Structures in Schizophrenia.

Zhao G, Denisova K, Sehatpour P, Long J, Gui W, Qiao J, Javitt DC, Wang Z.

PLoS One. 2016 May 13;11(5):e0155415. doi: 10.1371/journal.pone.0155415. eCollection 2016. Erratum in: PLoS One. 2016 Oct 11;11(10 ):e0164910.

11.

Synaptic and cellular changes induced by the schizophrenia susceptibility gene G72 are rescued by N-acetylcysteine treatment.

Pósfai B, Cserép C, Hegedüs P, Szabadits E, Otte DM, Zimmer A, Watanabe M, Freund TF, Nyiri G.

Transl Psychiatry. 2016 May 10;6:e807. doi: 10.1038/tp.2016.74.

12.

Atypical visual and somatosensory adaptation in schizophrenia-spectrum disorders.

Andrade GN, Butler JS, Peters GA, Molholm S, Foxe JJ.

Transl Psychiatry. 2016 May 10;6:e804. doi: 10.1038/tp.2016.63.

13.

Memantine augmentation in clozapine-refractory schizophrenia: a randomized, double-blind, placebo-controlled crossover study.

Veerman SR, Schulte PF, Smith JD, de Haan L.

Psychol Med. 2016 Jul;46(9):1909-21. doi: 10.1017/S0033291716000398. Epub 2016 Apr 6.

14.

Neuronal Activity-Induced Sterol Regulatory Element Binding Protein-1 (SREBP1) is Disrupted in Dysbindin-Null Mice-Potential Link to Cognitive Impairment in Schizophrenia.

Chen Y, Bang S, McMullen MF, Kazi H, Talbot K, Ho MX, Carlson G, Arnold SE, Ong WY, Kim SF.

Mol Neurobiol. 2017 Apr;54(3):1699-1709. doi: 10.1007/s12035-016-9773-x. Epub 2016 Feb 12.

PMID:
26873854
15.

Revisiting the Basic Symptom Concept: Toward Translating Risk Symptoms for Psychosis into Neurobiological Targets.

Schultze-Lutter F, Debbané M, Theodoridou A, Wood SJ, Raballo A, Michel C, Schmidt SJ, Kindler J, Ruhrmann S, Uhlhaas PJ.

Front Psychiatry. 2016 Jan 28;7:9. doi: 10.3389/fpsyt.2016.00009. eCollection 2016. Review.

16.

The Relative Contribution of NMDARs to Excitatory Postsynaptic Currents is Controlled by Ca(2+)-Induced Inactivation.

Valiullina F, Zakharova Y, Mukhtarov M, Draguhn A, Burnashev N, Rozov A.

Front Cell Neurosci. 2016 Jan 29;10:12. doi: 10.3389/fncel.2016.00012. eCollection 2016.

17.

Searching for cognitive enhancement in the Morris water maze: better and worse performance in D-amino acid oxidase knockout (Dao(-/-)) mice.

Pritchett D, Taylor AM, Barkus C, Engle SJ, Brandon NJ, Sharp T, Foster RG, Harrison PJ, Peirson SN, Bannerman DM.

Eur J Neurosci. 2016 Apr;43(7):979-89. doi: 10.1111/ejn.13192. Epub 2016 Mar 23.

18.

MPX-004 and MPX-007: New Pharmacological Tools to Study the Physiology of NMDA Receptors Containing the GluN2A Subunit.

Volkmann RA, Fanger CM, Anderson DR, Sirivolu VR, Paschetto K, Gordon E, Virginio C, Gleyzes M, Buisson B, Steidl E, Mierau SB, Fagiolini M, Menniti FS.

PLoS One. 2016 Feb 1;11(2):e0148129. doi: 10.1371/journal.pone.0148129. eCollection 2016. Erratum in: PLoS One. 2016;11(3):e0151452.

19.

Schizophrenia.

Owen MJ, Sawa A, Mortensen PB.

Lancet. 2016 Jul 2;388(10039):86-97. doi: 10.1016/S0140-6736(15)01121-6. Epub 2016 Jan 15. Review.

PMID:
26777917
20.

GluN2D N-Methyl-d-Aspartate Receptor Subunit Contribution to the Stimulation of Brain Activity and Gamma Oscillations by Ketamine: Implications for Schizophrenia.

Sapkota K, Mao Z, Synowicki P, Lieber D, Liu M, Ikezu T, Gautam V, Monaghan DT.

J Pharmacol Exp Ther. 2016 Mar;356(3):702-11. doi: 10.1124/jpet.115.230391. Epub 2015 Dec 16.

Supplemental Content

Support Center